Compare Abbott Laboratories (ABT) vs Aspen Aerogels Inc (ASPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Aspen Aerogels Inc — how do they compare? Abbott Laboratories trades at $95.48 (market cap $166.94B), while Aspen Aerogels Inc trades at $5.11 (market cap $425.99M). The key difference: Abbott Laboratories is far larger — about 391.9× Aspen Aerogels Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Aspen Aerogels Inc pays none. Which is the better fit depends on your goals.
| ABT | ASPN | |
|---|---|---|
Market Cap | $166.94B | $425.99M |
Sector | Health | Technology |
52-Week High | $136.62 | $8.82 |
52-Week Low | $82.57 | $2.57 |
Enterprise Value | $193.69B | $380.94M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ASPN trades at $5.47, down 1.97% today, with a bearish technical signal despite bullish moving averages. The company reported a Q1 2026 net loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility after an incident. Cash flow improved in 2026 projections, with net cash flow narrowing to -$17 million from -$63 million in 2025.
Outlook remains challenging with persistent losses and negative margins, but analyst sentiment is strongly bullish (83% buy ratings). Key risks include execution on facility restarts, EV demand volatility, and cash burn. The stock's investment case hinges on operational turnaround and revenue growth acceleration amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →
